Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Heat Biologics, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer-associated antigens together with a potent immune adjuvant. The company?s products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase I/II clinical trials for the bladder cancer treatment. It is also developing a cell line for the treatment of ovarian and triple negative breast cancer; and HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-58.55%||ROE||-68.91%||ROI|
|Current Ratio||9.85||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.12|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||11.13 M||Cash From Investing Activities||-110 K||Cash From Operating Activities||-4.46 M||Gross Profit|
|Net Profit||-3.91 M||Operating Profit||-3.98 M||Total Assets||22.83 M||Total Current Assets||22.15 M|
|Total Current Liabilities||2.25 M||Total Debt||2.73 M||Total Liabilities||3.43 M||Total Revenue|
|High 52 week||2.87||Low 52 week||0.84||Last close||0.84||Last change||-2.75%|
|RSI||14.09||Average true range||0.07||Beta||1.25||Volume||871.26 K|
|Simple moving average 20 days||-17.09%||Simple moving average 50 days||-25.87%||Simple moving average 200 days||-42.97%|
|Performance Week||-14.7%||Performance Month||-25.96%||Performance Quart||-41.79%||Performance Half||-47.9%|
|Performance Year||-53.62%||Performance Year-to-date||-13.87%||Volatility daily||2.84%||Volatility weekly||6.36%|
|Volatility monthly||13.04%||Volatility yearly||45.16%||Relative Volume||229.83%||Average Volume||511.19 K|
|New High||New Low|
2019-06-12 13:30:00 | HTBX: INDs To Be Filed Soon
2019-06-03 06:55:00 | Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure
2019-05-23 11:09:20 | Is Heat Biologics, Inc.'s NASDAQ:HTBX CEO Overpaid Relative To Its Peers?
2019-05-15 07:30:00 | Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update
2019-05-06 07:00:00 | Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai
2019-04-18 17:30:00 | Heat Biologics CEO to Present at the ThinkEquity Conference in New York City
2019-04-11 09:30:00 | HTBX: 2018 Financial & Operational Results
2019-04-02 08:00:00 | Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019
2019-03-28 07:30:00 | Heat Biologics Reports 2018 Results and Provides Corporate Update
2019-03-11 10:40:00 | HTBX: HS-110 Interim Update
2019-02-26 09:45:00 | These Four Healthcare Stocks Are Heating Up On Tuesday
2019-02-13 10:03:27 | What Type Of Shareholder Owns Heat Biologics, Inc.’s NASDAQ:HTBX?
2019-01-10 06:30:00 | Heat Biologics Provides Clinical and Business Update
2019-01-04 07:00:00 | Heat Biologics to Present at Biotech Showcase 2019 in California
2018-12-03 10:15:00 | HTBX: Plenty of Catalysts in 2019
2018-11-27 08:38:42 | Durham company rakes in another $13.8M through public offering
2018-11-26 16:00:00 | Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering
2018-11-23 08:15:00 | Detailed Research: Economic Perspectives on Whirlpool, GrafTech International, Thermon Group, White Mountains Insurance Group, Air Industries Group, and Heat Biologics — What Drives Growth in Today's Competitive Landscape
2018-11-21 15:21:00 | Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
2018-11-21 13:37:33 | Should You Be Concerned About Heat Biologics Inc’s NASDAQ:HTBX Historical Volatility?
2018-11-21 07:30:00 | Heat Biologics, Inc. Prices $12,000,000 Public Offering
2018-11-20 15:10:00 | Heat Biologics, Inc. Announces Proposed Public Offering
2018-11-15 07:00:00 | Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update
2018-10-22 07:00:00 | Heat Biologics to Present at Precision: Lung Cancer World R&D Summit
2018-10-10 07:00:00 | Heat Biologics to Present at the 2018 BIO Investor Forum
2018-09-26 15:16:17 | What does Heat Biologics Inc’s NASDAQ:HTBX Balance Sheet Tell Us About Its Future?
2018-08-29 09:45:00 | HTBX: Multiple Milestones on the Horizon
2018-08-15 16:21:04 | Heat Biologics Stock Is a Worthwhile, Speculative Bet
2018-08-14 07:30:00 | Heat Biologics Reports Second Quarter 2018 Results and Provides Corporate Update
2018-07-30 07:00:00 | Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks
2018-07-16 09:45:00 | HTBX: Heat Biologics: Making an ImPACT on Cancer
2018-06-29 07:10:00 | Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space
2018-06-06 13:22:21 | Is Heat Biologics Inc NASDAQ:HTBX Excessively Paying Its CEO?
2018-05-30 07:00:00 | Heat Biologics to Present at the 2018 BIO International Convention
2018-05-24 07:15:00 | Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks